Please assess the completion status of the following clinical trial:

Trial Title: Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Histological or cytological documented~* Resectable NSCLC of stage IIIA-N2 confirmed by mediastinoscopy or PET~* Naive therapy NSCLC~* Candidates should be tolerated with induction therapy and thoracotomy with ECOG performance status 0-2, adequate haematological and Hepatic- renal function and qualified lung function~* Enough tissue samples to perform gene analysis~Exclusion Criteria:~* Small cell lung cancer~* Pregnant or breast-feeding women~* Any unstable systemic disease~* Patients with exposure to investigational drug therapy or other concurrent anticancer therapy outside of this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Erlotinib targeted NSCLC population based on EGFR gene analysis(EGFR gene status: activating mutation)
- B (Type: ACTIVE_COMPARATOR): Non-erlotinib targeted NSCLC population based on EGFR gene analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).